Medizintechnik

Medizintechnik

Bain works alongside medical technology clients to develop and implement strategies that fuel cost-effective innovation and meet the needs of a broader range of constituents. We help you refine your understanding of your customers, develop a more flexible operating model, and expand into promising geographies and product categories.

What We Do

With disruptive changes altering the basis of competition, medtech companies may seek new opportunities to redefine business models, enter new markets and deploy their scale advantages in new ways. To thrive in this emerging environment, Bain’s teams of experts help medtech companies across the globe address a new set of priorities, including:

Recasting the understanding of the customer base.Medical technology companies must refresh their understanding of how they segment customers and update the segmentation over time dynamically, as opposed to static or snap-shot segmentation, which is less useful in this rapidly evolving market.

Mergers & Acquisitions. Bain helps medical technology companies significantly improve their odds of successful M&A with an approach that links acquisition strategy, due diligence and merger integration. Bain works closely with our clients to make their M&A transactions pay off by developing a clearly articulated strategy, integrating where it matters and acting quickly to create value for shareholders.

Moving to a more efficient R&D model. Successful medtech companies will focus on both internally and externally sourced innovation. They will shift from a design-to-ideal approach to a design-to-value one in commoditized medical product markets.

Investing to win in the remaining white spaces. Medical technology companies still have the opportunity to choose a few new areas for disruptive innovation and develop new medical device or equipment markets—both therapeutically as well as geographically.

Considering how to win in rapid-growth emerging markets. Emerging healthcare markets are complex, diverse and evolving, but companies operating in these regions can enjoy rapid growth rates. Winning requires carefully assessing where to play, creating the right product portfolios and distribution models, and, in many cases, finding the right deal partners.

Rationalizing manufacturing and G&A costs. Companies must maintain a strategic focus on costs in order to shed unnecessary expenses and reinforce areas of strength. A radical redesign of all processes with a zero-based budgeting approach can help change preconceived notions of how things have been done before.

Our Perspective

Much like pharmaceutical companies, medical technology companies face profit pools shifting away from the historically-innovative players to lower-margin sectors. While a few sectors of stability remain, the majority of the medical technology industry’s tried-and-tested formula for success is fundamentally changing. Three trends, in particular, are transforming the way the sector generates value in the largest historical profit pools:

The maturing—and slowing—pace and relative differentiation of innovation

The diminishing role of physicians in the purchasing process

The reduced ability to charge a premium for incremental healthcare product features and benefits

Healthcare reform across the globe is further accelerating these changes. While structural differences exist by category and country, macro trends in developed markets like the US and Europe are similar, such as the increased emphasis on comparative effectiveness, while emerging markets focus on low-cost solutions to improve access.